Coagulation

The Worldwide Electrosurgery Industry is Expected to Reach $8.4 Billion by 2028 at a 5.9% CAGR - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Health Technology, Health, Surgery, Lamina monopolar cell, Desiccation, Government, Bipolar, Electrocoagulation, Burns, Temperature, Dehydration, Defibrillation, Pain, Bleeding, Liver cancer, Critical care, Electrosurgery, Infection, Coagulation, Patient, Medical device, Medical imaging

The Global Electrosurgery Market size is expected to reach $8.4 billion by 2028, rising at a market growth of 5.9% CAGR during the forecast period.

Key Points: 
  • The Global Electrosurgery Market size is expected to reach $8.4 billion by 2028, rising at a market growth of 5.9% CAGR during the forecast period.
  • A high-frequency (radio frequency) alternating polarity electrical current is applied during electrosurgery to biological tissue to cut, coagulate, desiccate, or fulgurate tissue.
  • In hospital operating rooms or during outpatient treatments, electrosurgical devices are routinely utilized during surgical operations to assist prevent blood loss.
  • If sufficient precautions are not taken during the process, electrosurgery also carries a high risk of contamination.

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Retrieved on: 
Monday, November 14, 2022
Health, UEA, Technology, IDF, Laboratory, Pharmacy, Diabetes, Degenerative disease, Efficiency, School, Nasdaq, Time, Coagulation, World Diabetes Day, Internal medicine, Glycated hemoglobin, Patient, Risk, Norfolk and Norwich University Hospital, CV, SD, Norwich Medical School, GP, Infection, Prevalence, Disease, Solution, Pharmaceutical industry, Platform

LONDON, Nov. 14, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings. Used alongside the LumiraDx Platform, the test monitors known diabetic patients' HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.  Providing results in under seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient's side. The company announced the assay had achieved CE marking in late May of this year.

Key Points: 
  • Used alongside the LumiraDx Platform, the test monitors known diabetic patients' HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.
  • 1 The portability and flexibility of the LumiraDx Platform enables the LumiraDx HbA1c test to address the growing clinical need for accessible and reliable HbA1c testing in the community healthcare setting to aid in quicker clinical decision making.
  • The LumiraDx HbA1c test has a reportable range of 20 - 130 mmol/mol HbA1c (4.0 - 14.0% HbA1c).
  • The availability of an immediate, lab-comparable HbA1c test has been shown to improve patient outcomes through improved diabetes management.

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Retrieved on: 
Monday, November 14, 2022
Health, UEA, Technology, IDF, Laboratory, Pharmacy, Diabetes, Degenerative disease, Efficiency, School, Nasdaq, Time, Coagulation, World Diabetes Day, Internal medicine, Glycated hemoglobin, Patient, Risk, Norfolk and Norwich University Hospital, CV, SD, Norwich Medical School, GP, Infection, Prevalence, Disease, Solution, Pharmaceutical industry, Platform

LONDON, Nov. 14, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings. Used alongside the LumiraDx Platform, the test monitors known diabetic patients' HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.  Providing results in under seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient's side. The company announced the assay had achieved CE marking in late May of this year.

Key Points: 
  • Used alongside the LumiraDx Platform, the test monitors known diabetic patients' HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.
  • 1 The portability and flexibility of the LumiraDx Platform enables the LumiraDx HbA1c test to address the growing clinical need for accessible and reliable HbA1c testing in the community healthcare setting to aid in quicker clinical decision making.
  • The LumiraDx HbA1c test has a reportable range of 20 - 130 mmol/mol HbA1c (4.0 - 14.0% HbA1c).
  • The availability of an immediate, lab-comparable HbA1c test has been shown to improve patient outcomes through improved diabetes management.

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, IgA nephropathy, Private Securities Litigation Reform Act, Vera, Autoantibody, Viremia, U.S. Securities and Exchange Commission, Immunosuppression, Annual general meeting, Nasdaq, COMPASS, B cell, Cytokine, Society, BKV, Virus, Immunoglobulin A, B-cell activating factor, Coagulation, Disease, Mortality, Therapy, Chronic kidney disease, Lupus nephritis, Degenerative disease, Safety, BK virus, Proteinuria, Biomarker, Program, Polyomaviridae, Clinical trial, Standard of care, ASN, Patient, American Society of Nephrology, Pfizer, CEO, TACI, Infection, Security (finance), Kidney failure, Quarter, COVID-19, Bank, Pharmaceutical industry, Vaccine, BK

During the third quarter of 2022, we continued to make progress advancing our late-stage clinical pipeline of atacicept and MAU868, said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.

Key Points: 
  • During the third quarter of 2022, we continued to make progress advancing our late-stage clinical pipeline of atacicept and MAU868, said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.
  • IgAN is a common cause of kidney failure and there is a high unmet medical need for treatment of IgAN globally.
  • We are also pleased to announce initiation of our pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis.
  • Vera reported $114.4 million in cash, cash equivalents, and marketable securities as of September 30, 2022.

Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting 

Retrieved on: 
Thursday, November 3, 2022
ABR, Haemophilia, Fibrinolysis, Company, Male, Bleeding, Research, Maintenance, PWH, Society, Part, Industry, OLE, GLOBE, Coagulopathy, Safety, Single, ASH, COVID-19, Nasdaq, CNTA, APC, Coagulation, Omicron, Part Two, Annual report, U.S. Securities and Exchange Commission, Master of Science, Risk, Development, Time, SEC, Person, Policy, Patient, MD, Pharmacokinetics, Pharmaceutical industry, Delta

We look forward to presenting data from an additional 18-months of continued treatment with subcutaneous dosing of SerpinPC at the ASH Meeting.

Key Points: 
  • We look forward to presenting data from an additional 18-months of continued treatment with subcutaneous dosing of SerpinPC at the ASH Meeting.
  • The abstract accepted for oral presentation is detailed below and included in the online meeting program on the ASH Annual Meeting website.
  • Abstract Title: SerpinPC in persons with severe hemophilia (PW): Updated results from a multi-center, multi-part, first-in-human study.
  • Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients.

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 202

Retrieved on: 
Monday, October 17, 2022
Securities and Exchange Commission (Philippines), BK virus, B-cell activating factor, Therapy, Polyomaviridae, BKV, IgA nephropathy, Cytokine, BK, Degenerative disease, Society, Barratt, Patient, FRCP, Standard of care, Pfizer, Security (finance), B cell, Nephrology, Lupus nephritis, University, Autoantibody, Virus, Private Securities Litigation Reform Act, Biomarker, Vera, Immunosuppression, Immunoglobulin A, TACI, Coagulation, COVID-19, University of Leicester, Vaccine

BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.

Key Points: 
  • BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.
  • It is a leading cause of kidney transplant loss and transplant-associated morbidity; there are currently no approved treatments for BKV.
  • Vera holds an exclusive worldwide license from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for the development and commercialization of MAU868 in all indications.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID

Retrieved on: 
Wednesday, October 5, 2022
Time-invariant system, D2, Atherosclerosis, Sepsis, United States Department of Health and Human Services, Breathe Me, Biomedical Advanced Research and Development Authority, Disease, Hospital, Sickle cell disease, Coagulation, Indapamide, Pandemic, Spironolactone, Development, Human services, Pulmonary hypertension, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Education, COVID, Allergic rhinitis, Medicine, Patient, Thrombosis, Open philanthropy (doctrine), Ogletree, Degenerative disease, Immune system, Administration, Company, PGD2, Health, Hypoxemia, Department, Blood, A2, Biolink zones, Eplerenone, Prostaglandin D2, Thromboxane A2, Philanthropy, COVID-19, Mouth, Silicosis, Pharmaceutical industry, Ramatroban

BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.

Key Points: 
  • BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.
  • Ramatroban has been approved and used in Japan for over 20 years for treatment of allergic rhinitis by twice daily oral administration.
  • BioLink Life Sciences is a North Carolina based clinical research company that develops novel, proprietary pharmaceutical products via multiple regulatory pathways.
  • KARE Biosciences is also developing a novel, antihypertensive combination of indapamide, the best-in-class thiazide-like diuretic, in combination with a mineralocorticoid receptor antagonist (spironolactone or eplerenone).

Global Water and Wastewater Treatment Chemicals Market to Reach $52.01 Billion by 2029 at a CAGR of 4.7%

Retrieved on: 
Wednesday, September 28, 2022
Flocculation, Fertilizer, Detergent, Ageing, Lubricant, Coagulation, Prevalence, Coagulant, Disinfectant, Growth, Population growth, Environment, Maintenance, PH, Water, Public health, Urbanization, Water quality, Waterborne diseases, CAGR, Renewable energy, Sewage, Geography

The global wastewater treatment chemicals market is projected to reach $ 52.01 billion by 2029 at a CAGR of 4.7% from 2022 to 2029.

Key Points: 
  • The global wastewater treatment chemicals market is projected to reach $ 52.01 billion by 2029 at a CAGR of 4.7% from 2022 to 2029.
  • However, the high installation, maintenance, and operating costs of wastewater treatment plants restrain the growth of this market.
  • The water and wastewater treatment chemicals market is segmented based on type, source, end user, and geography.
  • Based on end user, the water and wastewater treatment chemicals market is segmented into residential, municipal, and industrial.

Global Water and Wastewater Treatment Chemicals Market Report 2022: Rapid Population Urbanization & Stringent Water Treatment Regulations Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Chemicals, Plastics, Manufacturing, Flocculation, Fertilizer, Detergent, Ageing, Lubricant, Coagulation, Prevalence, Coagulant, Disinfectant, Growth, Population growth, PH, Environment, Maintenance, Water, Public health, Urbanization, Water quality, Waterborne diseases, CAGR, Sewage, Renewable energy, Geography

The global wastewater treatment chemicals market is projected to reach $ 52.01 billion by 2029 at a CAGR of 4.7% from 2022 to 2029.

Key Points: 
  • The global wastewater treatment chemicals market is projected to reach $ 52.01 billion by 2029 at a CAGR of 4.7% from 2022 to 2029.
  • The growth of this market is driven by rapid population growth & urbanization, stringent water treatment regulations, regulatory and sustainability mandates concerning the environment, the lack of freshwater resources, and the increasing prevalence of waterborne diseases.
  • However, the high installation, maintenance, and operating costs of wastewater treatment plants restrain the growth of this market.
  • The growing demand for energy-efficient and advanced water treatment technologies is expected to create market growth opportunities.

The Worldwide Protein Engineering Industry is Projected to Reach $5.2 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Genetics, Health, Protein, Observation, Personal Software Services, Global, Porter's five forces analysis, Factor X, Software, Competitive analysis, Risk, COVID-19, Product, Geography, Growth, Neutralizing antibody, Ansoff Matrix, Insulin, Impact, Industry, Market development, USD, Investment, Emotion, Instrument, Contract, Vaccine, Coagulation, SWOT, Product-service system, CAGR, Fine chemical, Marketing, Risk management, Retail, Interferon, Technology

The Global Protein Engineering Market is estimated to be USD 3.1 Bn in 2022 and is projected to reach USD 5.26 Bn by 2027, growing at a CAGR of 11.16%.

Key Points: 
  • The Global Protein Engineering Market is estimated to be USD 3.1 Bn in 2022 and is projected to reach USD 5.26 Bn by 2027, growing at a CAGR of 11.16%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Protein Engineering Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Protein Engineering Market.
  • The Global Protein Engineering Market is segmented based on Product & Service, Protein Type, Technology, End User and Geography.